Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma
Article in Cells (May 2024)
The most recent citing publication is shown below. View this citation on Dimensions.
Resistance to Targeted Therapies in Multiple Myeloma
Overview of attention for book
Table of Contents
-
Altmetric BadgeBook Overview
-
Altmetric BadgeChapter 1 The Role of Targeted Therapy in Multiple Myeloma
-
Altmetric BadgeChapter 2 Lenalidomide
-
Altmetric BadgeChapter 3 Pomalidomide
-
Altmetric BadgeChapter 4 Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma
-
Altmetric BadgeChapter 5 Daratumumab
-
Altmetric BadgeChapter 6 Elotuzumab
-
Altmetric BadgeChapter 7 Histone Deacetylase Inhibitors
-
Altmetric BadgeChapter 8 Bone Targeted Therapies
-
Altmetric BadgeChapter 9 New Targeted Therapies for Multiple Myeloma Under Clinical Investigation
Attention for Chapter 4:
Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma